BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Cash Flow per Share

The Operating Cash Flow per Share of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 0.77 CNY. In the previous year, Operating Cash Flow per Share was 0.58 CNY — a change of 32.23% (higher).

Cash Flow per Share

0.77CNY

YoY

32.23%

Last updated:

Operating Cash Flow per Share of BrightGene Bio-Medical Technology Co is 2025 0.77 CNY. Operating Cash Flow per Share of BrightGene Bio-Medical Technology Co was 2024 0.58 CNY. It decreases by 32.23% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
0.15 CNY
Jan 1, 2019
0.15 CNY
Jan 1, 2020
0.38 CNY
Jan 1, 2021
0.43 CNY
Jan 1, 2022
0.74 CNY
Jan 1, 2023
0.46 CNY
Jan 1, 2024
0.58 CNY
Jan 1, 2025
0.77 CNY
The BrightGene Bio-Medical Technology Co Cash Flow per Share history
YEARCash Flow per ShareYoY
0.77CNY+32.23%
0.58CNY+26.08%
0.46CNY-37.43%
0.74CNY+71.56%
0.43CNY+13.28%
0.38CNY+153.42%
0.15CNY-1.08%
0.15CNY+78.90%
0.08CNY+20.29%
0.07CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Operating Cash Flow per Share of BrightGene Bio-Medical Technology Co is 0.77 CNY in 2025.

Operating Cash Flow per Share of BrightGene Bio-Medical Technology Co changed from 0.58 CNY to 0.77 CNY, representing a 32.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co